Faced with a PhIII flop in NASH, Gilead is sequencing 15,000 patients to find new drugs

Now well into its campaign to develop a new cocktail therapy for NASH — which has initially proved unsuccessful in its first pivotal study — Gilead is going back to the genetic drawing board in search of some added inspiration.

The big biotech has struck a deal with the Renown Institute for Health Innovation, offering to foot the bill for their work sequencing the genes of 15,000 people with NASH and nonalcoholic fatty liver disease and compare them against a backdrop of 40,000 healthy people in Nevada.